Variant of hyper-IgE syndrome: the differentiation from atopic dermatitis is important because of treatment and prognosis.
The hyper-IgE syndrome is characterized clinically by recurrent staphylococcal abscesses of the skin, lungs and other sites from infancy. Affected patients also have a pruritic dermatitis that differs in character and distribution from lesions of atopic dermatitis. Most lack other signs of atopic disease, develop persistent pneumatoceles and have osteopenia. Laboratory abnormalities include the consistent presence of marked hyperimmunoglobulinemia E and eosinophilia of blood, sputum and tissues. They may have other inconsistent abnormalities of humoral and cellular immune responses and sometimes of phagocytic cell chemotactic responsiveness. Other clinical problems reported in such patients have included lymphomas, cryptococcal meningitis and cutaneous fungal disease. An 18-year-old male patient with a variant of the hyper-IgE syndrome, which he had acquired after a measles attack at the age of 5 years, suffered from recurrent ulcerative dermatitis and lymph node abscesses. Immunological investigation revealed an excessively elevated total serum IgE level (46,850 IU/ml), the presence of specific IgE to staphylococci, and quantitative and functional deficiency of IgG2. Skin and serological (radioallergosorbent) tests to inhalant and nutritive allergens were negative. Differentiation from atopic dermatitis should be made, because a long-term antistaphylococcal regime not only improves skin lesions but hinders the occurrence of lung abscesses and pneumatoceles.
Hochreutener
H
H
Division of Allergy, Dermatology Clinic, University Hospital, Zurich, Switzerland.
Wüthrich
B
B
Huwyler
T
T
Schopfer
K
K
Seger
R
R
Baerlocher
K
K
D000038:Abscess / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D000293:Adolescent; D000907:Antibodies, Bacterial / Q000032:analysis; D003876:Dermatitis, Atopic / Q000175:diagnosis* / Q000473:pathology; D003937:Diagnosis, Differential; D004802:Eosinophilia / Q000175:diagnosis; D005436:Floxacillin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007073:Immunoglobulin E / Q000032:analysis* / Q000276:immunology; D008297:Male; D011379:Prognosis; D012008:Recurrence; D013207:Staphylococcal Skin Infections / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D013210:Staphylococcus / Q000276:immunology; D013577:Syndrome
D000907:Antibodies, Bacterial; D007073:Immunoglobulin E; D005436:Floxacillin